Skip to main content
Top
Published in: Inflammation 2/2018

01-03-2018 | ORIGINAL ARTICLE

Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8+T Cells and NK Cells

Authors: Jiantao Li, Gang Qiu, Baoshuan Fang, Xiaohui Dai, Jianhui Cai

Published in: Inflammation | Issue 2/2018

Login to get access

Abstract

To investigate the potential role of interleukin-18 (IL-18) in immunomodulation during tumorigenesis of esophageal carcinoma and elucidate the underlying molecular mechanism, we employed IL-18 knockout mice for this purpose. Carcinogen 4-nitroquinoline 1-oxide (4NQO) was administrated in drinking water to induce occurrence of esophageal squamous cell carcinoma (ESCC). T cell activation as indicated by the surface CD molecules was analyzed with flow cytometry. The serous content of interferon-γ (IFN-γ) along with other cytokines was determined by inflammatory human cytokine cytometric bead array. The cytotoxicity assay was performed by co-culture of tumor cells with immune cells and relative cell viability was determined by lactate dehydrogenase (LDH) assay. Apoptotic cells were stained with Annexin-V/propidium iodide (PI) and analyzed by flow cytometry. Cell proliferation was measured with Cell Counting Kit-8 (CCK-8) assay. Our data demonstrated that deficiency of IL-18 promoted the progression and development of 4NQO-induced ESCC. Loss of IL-18 suppressed the activation of T cells in the esophagus. Deficiency of IL-18 inhibited the IFN-γ production by CD8+ T cells and natural killer (NK) cells. Absence of IL-18 inhibited the cytotoxicity of CD8+ T cells and NK cell in vitro. Moreover, deficiency of IL-18 promoted the apoptosis of CD8+ T cells and inhibited the proliferation of CD8+ T cells in vitro. Our data elucidated the immunomodulatory role of IL-18 during tumorigenesis of ESCC, whose deficiency compromised antitumor immunity and contributed to immune escape of esophageal carcinoma. Our results also indicated the therapeutic potential of exogenous IL-18 against ESCC, which warrants further investigations.
Literature
1.
go back to reference Torre, L.A., F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal. 2015. Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians 65: 87–108. Torre, L.A., F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal. 2015. Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians 65: 87–108.
2.
go back to reference Lozano, R., M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095–2128.CrossRefPubMed Lozano, R., M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095–2128.CrossRefPubMed
3.
go back to reference Enzinger, P.C., and R.J. Mayer. 2003. Esophageal cancer. The New England Journal of Medicine 349: 2241–2252.CrossRefPubMed Enzinger, P.C., and R.J. Mayer. 2003. Esophageal cancer. The New England Journal of Medicine 349: 2241–2252.CrossRefPubMed
4.
go back to reference Prabhu, A., K.O. Obi, and J.H. Rubenstein. 2014. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: A meta-analysis. The American Journal of Gastroenterology 109: 822–827.CrossRefPubMed Prabhu, A., K.O. Obi, and J.H. Rubenstein. 2014. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: A meta-analysis. The American Journal of Gastroenterology 109: 822–827.CrossRefPubMed
5.
go back to reference Zhang, H.Z., G.F. Jin, and H.B. Shen. 2012. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chinese Journal of Cancer 31: 281–286.CrossRefPubMedCentralPubMed Zhang, H.Z., G.F. Jin, and H.B. Shen. 2012. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chinese Journal of Cancer 31: 281–286.CrossRefPubMedCentralPubMed
6.
go back to reference de Jonge, P.J., M. van Blankenstein, W.M. Grady, and E.J. Kuipers. 2014. Barrett’s oesophagus: Epidemiology, cancer risk and implications for management. Gut 63: 191–202.CrossRefPubMed de Jonge, P.J., M. van Blankenstein, W.M. Grady, and E.J. Kuipers. 2014. Barrett’s oesophagus: Epidemiology, cancer risk and implications for management. Gut 63: 191–202.CrossRefPubMed
7.
go back to reference Stahl M., Mariette C., Haustermans K., Cervantes A., Arnold D., Group E.G.W. 2013. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6:vi51-56. Stahl M., Mariette C., Haustermans K., Cervantes A., Arnold D., Group E.G.W. 2013. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6:vi51-56.
8.
go back to reference Biet, F., C. Locht, and L. Kremer. 2002. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) 80: 147–162.CrossRef Biet, F., C. Locht, and L. Kremer. 2002. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) 80: 147–162.CrossRef
9.
10.
go back to reference Li, K., L. Wei, Y. Huang, Y. Wu, M. Su, X. Pang, et al. 2016. Leptin promotes breast cancer cell migration and invasion via IL-18 expression and secretion. International Journal of Oncology 48: 2479–2487.CrossRefPubMed Li, K., L. Wei, Y. Huang, Y. Wu, M. Su, X. Pang, et al. 2016. Leptin promotes breast cancer cell migration and invasion via IL-18 expression and secretion. International Journal of Oncology 48: 2479–2487.CrossRefPubMed
11.
go back to reference Dwivedi, S., A. Goel, S. Khattri, A. Mandhani, P. Sharma, S. Misra, et al. 2015. Genetic variability at promoters of IL-18 (pro-) and IL-10 (anti-) inflammatory gene affects susceptibility and their circulating serum levels: An explorative study of prostate cancer patients in North Indian populations. Cytokine 74: 117–122.CrossRefPubMed Dwivedi, S., A. Goel, S. Khattri, A. Mandhani, P. Sharma, S. Misra, et al. 2015. Genetic variability at promoters of IL-18 (pro-) and IL-10 (anti-) inflammatory gene affects susceptibility and their circulating serum levels: An explorative study of prostate cancer patients in North Indian populations. Cytokine 74: 117–122.CrossRefPubMed
12.
go back to reference Liu, J.M., J.N. Liu, M.T. Wei, Y.Z. He, Y. Zhou, X.B. Song, et al. 2013. Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population. Genetics and Molecular Research 12: 820–829.CrossRefPubMed Liu, J.M., J.N. Liu, M.T. Wei, Y.Z. He, Y. Zhou, X.B. Song, et al. 2013. Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population. Genetics and Molecular Research 12: 820–829.CrossRefPubMed
13.
go back to reference Carbotti, G., G. Barisione, A.M. Orengo, A. Brizzolara, I. Airoldi, M. Bagnoli, et al. 2013. The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. Clinical Cancer Research 19: 4611–4620.CrossRefPubMed Carbotti, G., G. Barisione, A.M. Orengo, A. Brizzolara, I. Airoldi, M. Bagnoli, et al. 2013. The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. Clinical Cancer Research 19: 4611–4620.CrossRefPubMed
14.
go back to reference Terme, M., E. Ullrich, L. Aymeric, K. Meinhardt, J.D. Coudert, M. Desbois, et al. 2012. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Research 72: 2757–2767.CrossRefPubMed Terme, M., E. Ullrich, L. Aymeric, K. Meinhardt, J.D. Coudert, M. Desbois, et al. 2012. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Research 72: 2757–2767.CrossRefPubMed
15.
go back to reference Alagkiozidis, I., A. Facciabene, M. Tsiatas, C. Carpenito, F. Benencia, S. Adams, et al. 2011. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. Journal of Translational Medicine 9: 77.CrossRefPubMedCentralPubMed Alagkiozidis, I., A. Facciabene, M. Tsiatas, C. Carpenito, F. Benencia, S. Adams, et al. 2011. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. Journal of Translational Medicine 9: 77.CrossRefPubMedCentralPubMed
16.
go back to reference Kim, J., C. Kim, T.S. Kim, S.I. Bang, Y. Yang, H. Park, et al. 2006. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochemical and Biophysical Research Communications 344: 1284–1289.CrossRefPubMed Kim, J., C. Kim, T.S. Kim, S.I. Bang, Y. Yang, H. Park, et al. 2006. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochemical and Biophysical Research Communications 344: 1284–1289.CrossRefPubMed
17.
go back to reference Xu, X., C. Song, Z. Chen, C. Yu, Y. Wang, Y. Tang, et al. 2017. Downregulation of HuR inhibits the progression of esophageal cancer through Interleukin-18. Cancer Res Treat. Xu, X., C. Song, Z. Chen, C. Yu, Y. Wang, Y. Tang, et al. 2017. Downregulation of HuR inhibits the progression of esophageal cancer through Interleukin-18. Cancer Res Treat.
18.
go back to reference Madankumar, A., S. Jayakumar, K. Gokuladhas, B. Rajan, S. Raghunandhakumar, S. Asokkumar, et al. 2013. Geraniol modulates tongue and hepatic phase I and phase II conjugation activities and may contribute directly to the chemopreventive activity against experimental oral carcinogenesis. European Journal of Pharmacology 705: 148–155.CrossRefPubMed Madankumar, A., S. Jayakumar, K. Gokuladhas, B. Rajan, S. Raghunandhakumar, S. Asokkumar, et al. 2013. Geraniol modulates tongue and hepatic phase I and phase II conjugation activities and may contribute directly to the chemopreventive activity against experimental oral carcinogenesis. European Journal of Pharmacology 705: 148–155.CrossRefPubMed
19.
go back to reference Matthews, J.B., G.I. Mason, C.M. Scully, and S.S. Prime. 1986. In situ characterisation of the oral mucosal inflammatory cell response of rats induced by 4-nitroquinoline-N-oxide. Carcinogenesis 7: 783–788.CrossRefPubMed Matthews, J.B., G.I. Mason, C.M. Scully, and S.S. Prime. 1986. In situ characterisation of the oral mucosal inflammatory cell response of rats induced by 4-nitroquinoline-N-oxide. Carcinogenesis 7: 783–788.CrossRefPubMed
20.
go back to reference Tang, X.H., B. Knudsen, D. Bemis, S. Tickoo, and L.J. Gudas. 2004. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clinical Cancer Research 10: 301–313.CrossRefPubMed Tang, X.H., B. Knudsen, D. Bemis, S. Tickoo, and L.J. Gudas. 2004. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clinical Cancer Research 10: 301–313.CrossRefPubMed
21.
go back to reference Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA: a Cancer Journal for Clinicians 64: 9–29. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA: a Cancer Journal for Clinicians 64: 9–29.
22.
go back to reference Wu, I.C., C.C. Wu, C.Y. Lu, W.H. Hsu, M.C. Wu, J.Y. Lee, et al. 2013. Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One 8: e55834.CrossRefPubMedCentralPubMed Wu, I.C., C.C. Wu, C.Y. Lu, W.H. Hsu, M.C. Wu, J.Y. Lee, et al. 2013. Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One 8: e55834.CrossRefPubMedCentralPubMed
23.
go back to reference Pennathur, A., M.K. Gibson, B.A. Jobe, and J.D. Luketich. 2013. Oesophageal carcinoma. Lancet 381: 400–412.CrossRefPubMed Pennathur, A., M.K. Gibson, B.A. Jobe, and J.D. Luketich. 2013. Oesophageal carcinoma. Lancet 381: 400–412.CrossRefPubMed
24.
go back to reference Crusz, S.M., and F.R. Balkwill. 2015. Inflammation and cancer: Advances and new agents. Nature Reviews. Clinical Oncology 12: 584–596.CrossRefPubMed Crusz, S.M., and F.R. Balkwill. 2015. Inflammation and cancer: Advances and new agents. Nature Reviews. Clinical Oncology 12: 584–596.CrossRefPubMed
25.
go back to reference Cho, W.C., C.K. Kwan, S. Yau, P.P. So, P.C. Poon, and J.S. Au. 2011. The role of inflammation in the pathogenesis of lung cancer. Expert Opinion on Therapeutic Targets 15: 1127–1137.CrossRefPubMed Cho, W.C., C.K. Kwan, S. Yau, P.P. So, P.C. Poon, and J.S. Au. 2011. The role of inflammation in the pathogenesis of lung cancer. Expert Opinion on Therapeutic Targets 15: 1127–1137.CrossRefPubMed
26.
go back to reference Anestakis, D., S. Petanidis, S. Kalyvas, C.M. Nday, O. Tsave, E. Kioseoglou, et al. 2015. Mechanisms and applications of interleukins in cancer immunotherapy. International Journal of Molecular Sciences 16: 1691–1710.CrossRefPubMedCentralPubMed Anestakis, D., S. Petanidis, S. Kalyvas, C.M. Nday, O. Tsave, E. Kioseoglou, et al. 2015. Mechanisms and applications of interleukins in cancer immunotherapy. International Journal of Molecular Sciences 16: 1691–1710.CrossRefPubMedCentralPubMed
27.
go back to reference Gao, Y.B., Z.L. Chen, J.G. Li, X.D. Hu, X.J. Shi, Z.M. Sun, et al. 2014. Genetic landscape of esophageal squamous cell carcinoma. Nature Genetics 46: 1097–1102.CrossRefPubMed Gao, Y.B., Z.L. Chen, J.G. Li, X.D. Hu, X.J. Shi, Z.M. Sun, et al. 2014. Genetic landscape of esophageal squamous cell carcinoma. Nature Genetics 46: 1097–1102.CrossRefPubMed
28.
go back to reference Denies, S., L. Cicchelero, I. Van Audenhove, and N.N. Sanders. 2014. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. Journal of Controlled Release 187: 175–182.CrossRefPubMed Denies, S., L. Cicchelero, I. Van Audenhove, and N.N. Sanders. 2014. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. Journal of Controlled Release 187: 175–182.CrossRefPubMed
29.
go back to reference Yuan, L., H. Zhao, L. Zhang, and X. Liu. 2013. The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumour Biology 34: 3027–3034.CrossRefPubMed Yuan, L., H. Zhao, L. Zhang, and X. Liu. 2013. The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumour Biology 34: 3027–3034.CrossRefPubMed
30.
go back to reference Zhao, N., X. Li, X. He, Y. Qiu, L. Zhu, and F. Qi. 2013. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer. The Journal of Gene Medicine 15: 366–374.CrossRefPubMed Zhao, N., X. Li, X. He, Y. Qiu, L. Zhu, and F. Qi. 2013. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer. The Journal of Gene Medicine 15: 366–374.CrossRefPubMed
31.
go back to reference Yoshimoto, T., N. Morishima, M. Okumura, Y. Chiba, M. Xu, and J. Mizuguchi. 2009. Interleukins and cancer immunotherapy. Immunotherapy 1: 825–844.CrossRefPubMed Yoshimoto, T., N. Morishima, M. Okumura, Y. Chiba, M. Xu, and J. Mizuguchi. 2009. Interleukins and cancer immunotherapy. Immunotherapy 1: 825–844.CrossRefPubMed
32.
go back to reference Zhang, X., L. Zhang, W. Xu, H. Qian, S. Ye, W. Zhu, et al. 2013. Experimental therapy for lung cancer: Umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Current Cancer Drug Targets 13: 92–102.CrossRefPubMed Zhang, X., L. Zhang, W. Xu, H. Qian, S. Ye, W. Zhu, et al. 2013. Experimental therapy for lung cancer: Umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Current Cancer Drug Targets 13: 92–102.CrossRefPubMed
33.
go back to reference Kaiga, T., M. Sato, H. Kaneda, Y. Iwakura, T. Takayama, and H. Tahara. 2007. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. Journal of Immunology 178: 7571–7580.CrossRef Kaiga, T., M. Sato, H. Kaneda, Y. Iwakura, T. Takayama, and H. Tahara. 2007. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. Journal of Immunology 178: 7571–7580.CrossRef
34.
go back to reference Yang, C., H. Cao, N. Liu, K. Xu, M. Ding, and L.J. Mao. 2016. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma. Drug Design, Development and Therapy 10: 3755–3761.CrossRefPubMedCentralPubMed Yang, C., H. Cao, N. Liu, K. Xu, M. Ding, and L.J. Mao. 2016. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma. Drug Design, Development and Therapy 10: 3755–3761.CrossRefPubMedCentralPubMed
Metadata
Title
Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8+T Cells and NK Cells
Authors
Jiantao Li
Gang Qiu
Baoshuan Fang
Xiaohui Dai
Jianhui Cai
Publication date
01-03-2018
Publisher
Springer US
Published in
Inflammation / Issue 2/2018
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0721-3

Other articles of this Issue 2/2018

Inflammation 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.